NASDAQ:CERS

Cerus - CERS Stock Forecast, Price & News

$4.70

-0.12 (-2.49%)

(As of 08/19/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.68
▼
$4.77
50-Day Range: $4.43
▼
$5.83
52-Week Range: $4.34
▼
$8.06

Volume: 1.44 million shs
Average Volume: 1.82 million shs
Market Capitalization: $832.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Cerus MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.12
Based on 3 Articles This Week
Insider Trading: Selling Shares
$51,200 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.23) to ($0.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

902nd out of 1,116 stocks

Surgical & Medical Instruments Industry

86th out of 112 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Cerus.

5.0

Short Interest

Percentage of Shares Shorted
3.42% of the float of Cerus has been sold short.
Short Interest Ratio / Days to Cover
Cerus has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cerus has recently decreased by 12.69%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cerus does not currently pay a dividend.
Dividend Growth
Cerus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERS.

2.3

News and Social Media Coverage

News Sentiment
Cerus has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cerus this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
2 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,200.00 in company stock.
Percentage Held by Insiders
Only 7.33% of the stock of Cerus is held by insiders.
Percentage Held by Institutions
85.56% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cerus are expected to grow in the coming year, from ($0.23) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerus is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerus is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerus has a P/B Ratio of 10.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Trading Down 1.2 %

Cerus stock opened at $4.82 on Friday. Cerus has a 12-month low of $4.34 and a 12-month high of $8.06. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.73. The stock has a market capitalization of $853.57 million, a PE ratio of -20.08 and a beta of 1.07. The firm has a 50 day simple moving average of $5.32 and a 200-day simple moving average of $5.25.

Insiders Place Their Bets

In other Cerus news, insider Richard J. Benjamin sold 10,000 shares of the stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $5.12, for a total transaction of $51,200.00. Following the completion of the transaction, the insider now directly owns 172,665 shares of the company's stock, valued at approximately $884,044.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.33% of the stock is currently owned by insiders.

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

August 17, 2022 | benzinga.com

Cerus Earnings Perspective: Return On Capital Employed - Benzinga

August 12, 2022 | businesswire.com

Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency - Business Wire

August 19, 2022 | Investing Trends (Ad)

Is the US Military Secretly Under Chinese Control?

Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...

August 12, 2022 | finance.yahoo.com

Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency

August 5, 2022 | fool.com

Cerus (CERS) Q2 2022 Earnings Call Transcript - The Motley Fool

August 5, 2022 | finance.yahoo.com

Cerus (CERS) Q2 2022 Earnings Call Transcript

August 5, 2022 | seekingalpha.com

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M (NASDAQ:CERS) - Seeking Alpha

August 4, 2022 | finance.yahoo.com

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range - Yahoo Finance

August 19, 2022 | Investing Trends (Ad)

Potential Gold Rush For Investors Sparked By USA Vs. China Trade War

Right now, China has the US Military in a stranglehold. They hold a monopoly on one of our most CRITICAL defense elements. But thanks to executive orders from both Biden and Trump...

August 4, 2022 | businesswire.com

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range - Business Wire

August 4, 2022 | finance.yahoo.com

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range

August 3, 2022 | nasdaq.com

CERS Makes Bullish Cross Above Critical Moving Average - Nasdaq

August 1, 2022 | nasdaq.com

What Kind Of Investors Own Most Of Cerus Corporation (NASDAQ:CERS)? - Nasdaq

August 1, 2022 | nasdaq.com

Have Insiders Sold Apogee Enterprises, Inc. (NASDAQ:APOG) Shares Recently? - Nasdaq

July 31, 2022 | nasdaq.com

Sprouts Farmers Market, Inc.'s (NASDAQ:SFM) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Nasdaq

July 31, 2022 | nasdaq.com

Richard Barlow Is The Founder of Wejo Group Limited (NASDAQ:WEJO) And They Just Picked Up 1.7% More Shares - Nasdaq

July 31, 2022 | nasdaq.com

Be Sure To Check Out First Community Bankshares, Inc. (NASDAQ:FCBC) Before It Goes Ex-Dividend - Nasdaq

July 31, 2022 | nasdaq.com

Why You Might Be Interested In Premier Financial Corp. (NASDAQ:PFC) For Its Upcoming Dividend - Nasdaq

July 26, 2022 | uk.finance.yahoo.com

The Global Apheresis Devices Market is expected to grow by $ 915.84 mn during 2022-2026, accelerating at a CAGR of 6.3% during the forecast period - Yahoo Finance UK

July 26, 2022 | finance.yahoo.com

The Global Apheresis Devices Market is expected to grow by $ 915.84 mn during 2022-2026, accelerating at a CAGR of 6.3% during the forecast period - Yahoo Finance

July 21, 2022 | businesswire.com

Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022 - Business Wire

July 21, 2022 | finance.yahoo.com

Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022

July 14, 2022 | seekingalpha.com

Cerus Stock: Technicals Supportive Of Near-Term Upside (NASDAQ:CERS) - Seeking Alpha

July 14, 2022 | finance.yahoo.com

Cerus (CERS) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 13, 2022 | fool.com

The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common - The Motley Fool

July 13, 2022 | finance.yahoo.com

The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common

July 6, 2022 | businesswire.com

Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings: 11/02/2021
Today: 8/19/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:CERS
CUSIP: 15708510
CIK: 1020214
Web: www.cerus.com
Phone: (925) 288-6000
Fax: 925-288-6001
Employees: 631
Year Founded: 1991

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,380,000.00
Net Margins: -27.34%
Pretax Margin: -27.16%
Return on Equity: -52.16%
Return on Assets: -18.88%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 2.08
Quick Ratio: 1.73

Sales & Book Value

Annual Sales: $130.86 million
Price / Sales: 6.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.43 per share
Price / Book: 10.93

Miscellaneous

Outstanding Shares: 177,090,000
Free Float: 164,109,000
Market Cap: $832.32 million
Optionable: Optionable
Beta: 1.07

Social Links

Key Executives

Mr. William M. Greenman (Age 55)
Pres, CEO & Director
Comp: $1.25M

Dr. Laurence M. Corash (Age 78)
Co-Founder & Chief Scientific Officer
Comp: $697.77k

Mr. Kevin D. Green (Age 50)
VP of Fin. & CFO
Comp: $698.15k

Mr. Vivek K. Jayaraman (Age 47)
Chief Operating Officer
Comp: $845.3k

Dr. Richard J. Benjamin (Age 62)
Chief Medical Officer
Comp: $718.64k

Ms. Lori L. Roll
VP of Admin. & Corp. Sec.

Mr. Matthew M. Notarianni
Sr. Director of Investor Relations

Ms. Chrystal N. Menard (Age 51)
Chief Legal Officer & Gen. Counsel

Lainie Corten
VP of Global Marketing

Ms. Carol M. Moore (Age 72)
Sr. VP of Regulatory Affairs, Quality & Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERS Stock - Frequently Asked Questions

How have CERS shares performed in 2022?: Cerus' stock was trading at $6.81 at the start of the year. Since then, CERS stock has decreased by 31.0% and is now trading at $4.70.
View the best growth stocks for 2022 here.
When is Cerus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our CERS earnings forecast.
How were Cerus' earnings last quarter?: Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The biotechnology company had revenue of $36.13 million for the quarter, compared to analysts' expectations of $31.60 million. Cerus had a negative trailing twelve-month return on equity of 52.16% and a negative net margin of 27.34%. During the same quarter in the prior year, the firm earned ($0.08) EPS.
What guidance has Cerus issued on next quarter's earnings?: Cerus issued an update on its FY 2022 earnings guidance on Thursday, August, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $176.65 million.
What is William M. (Obi) Greenman's approval rating as Cerus' CEO?: 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cerus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?: Cerus trades on the NASDAQ under the ticker symbol "CERS."
Who are Cerus' major shareholders?: Cerus' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (9.67%), Sumitomo Mitsui Trust Holdings Inc. (5.82%), Nikko Asset Management Americas Inc. (5.82%), Primecap Management Co. CA (5.23%), State Street Corp (2.53%) and Assenagon Asset Management S.A. (1.69%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.
How do I buy shares of Cerus?: Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cerus' stock price today?: One share of CERS stock can currently be purchased for approximately $4.70.
How much money does Cerus make?: Cerus (NASDAQ:CERS) has a market capitalization of $832.32 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.
How many employees does Cerus have?: The company employs 631 workers across the globe.
When was Cerus founded?: Cerus was founded in 1991.
How can I contact Cerus?: Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 8/19/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Cerus - CERS Stock Forecast, Price & News

Cerus MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cerus (NASDAQ:CERS) Stock

Cerus Trading Down 1.2 %

Insiders Place Their Bets

CERS Stock News Headlines

CERS Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

CERS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™